Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis

Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis
Alumis and Acelyrin to merge in all-stock deal
Alumis eyes $300 million in proceeds in IPO
2.92BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US0223071020
CUSIP
-
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
2.88
Dividend Share
-
Dividend Yield
-
Earnings Share
-1.78
Wall Street Target Price
39.90
EPS Estimate Current Year
-2.90
EPS Estimate Next Year
-2.95
EPS Estimate Current Quarter
-0.78
EPS Estimate Next Quarter
-0.69
Most Recent Quarter
-
Revenue TTM
8,402,000
Gross Profit TTM
8,402,000
EBITDA
-435,260,992
Profit Margin
0.00%
Return On Assets TTM
-58.79%
Return On Equity TTM
-64.57%
Revenue Per Share TTM
0.082
Qtly Revenue Growth YOY
-90.00%
Diluted Eps TTM
-1.78
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
320.9302
Price Book MRQ
9.9886
Enterprise Value Revenue
113
Enterprise Value EBITDA
0
283.89
3.04%136.01
1.42%17.40
0.75%294.30
0.33%803.19
0.00%630.30
-11.57%434.31
-3.61%797.77
-2.91%147.30
-1.49%68.51
-0.71%